News

Genprex Announces Positive Interim Data from Phase II Clinical Trial of Oncoprex™ for Late Stage Non-Small Cell Lung Cancer

Genprex, Inc. today announced positive interim data from an ongoing Phase II clinical trial (NCT01455389) evaluating its investigational immunogene therapy candidate Oncoprex™ in combination with the tyrosine kinase inhibitor (TKI) erlotinib (Tarceva®).

Read More

Genprex To Present at Biotech Showcase 2017

Genprex, Inc. announced that management will be presenting at Biotech Showcase 2017 to be held January 9-11, 2017 in San Francisco, concurrently with the J.P. Morgan Healthcare Conference.

Read More

Genprex Retains ICR Healthcare as Integrated Strategic Communications Counsel

Genprex, Inc. has retained ICR Healthcare, a specialty healthcare practice within a leading strategic communications and advisory firm, to develop and implement an integrated strategic communications program.

Read More

Genprex Expands Executive Management Team and Completes Funding

Genprex, Inc. announces the appointment of Julien Pham, MD, MPH, as Chief Operating Officer.

Read More

Genprex Signs Capital Markets Advisory Agreement with Network 1 Financial as Part of an Overall Financing Plan

Genprex, Inc. announced today that it has signed a capital markets advisory agreement with Network 1 Financial Securities, Inc. as a first step in the Company’s plan for funding its capital needs as it enters into advanced clinical trials for its lead drug candidate.

Read More

Genprex Begins Phase II Clinical Trial for Lung Cancer

Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients.

Read More

Clinical Trial Highlights Positive Oncoprex Results in Lung Cancer Patients

A clinical trial has demonstrated that Oncoprex® (TUSC2 nanoparticles) can be safely administered in advanced lung cancer patients to halt cancer or shrink primary and metastatic tumors in some patients.

Read More

Oncoprex Shows Synergistic Tumor Suppression in Combination with AKT Inhibitor MK2206

New data demonstrating the anti-cancer activities of Oncoprex® were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago IL.

Read More

Genprex Announces New Patent Issuance in Japan

A new patent covering tumor suppression technologies, including the company’s lead product candidate Oncoprex™, was recently awarded to The University of Texas System by the Japan Patent Office.

Read More

Genprex announces new branding

Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today that its first product candidate, the nanomolecular cancer therapy CNVN202, will be branded as Oncoprex™.

Read More